The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
988
November 22, 1996
View Complete Issue         Table of Contents 2019 
Sodium Phenylbutyrate for Urea Cycle Enzyme Deficiencies
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sodium Phenylbutyrate for Urea Cycle Enzyme Deficiencies
November 22, 1996 (Issue: 988)
Sodium phenylbutyrate, an "orphan drug,"has recently been marketed for the treatment of patients with urea cycle disorders caused by a deficiency in one of the following hepatic enzymes: carbamyl phosphate synthetase (CPS), ornithine transcarbamylase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sodium Phenylbutyrate for Urea Cycle Enzyme Deficiencies
Article code: 988c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.